Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Potassium pills may slow kidney decline in CKD patients

NCT ID NCT03253172

Disease control Sponsor: Erasmus Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 2 times

Summary

This study tests whether taking potassium supplements can slow down kidney function loss in people with moderate-to-severe chronic kidney disease (CKD) and high blood pressure. About 532 adults with CKD stage 3b or 4 will receive potassium or a placebo. The goal is to see if potassium can protect the kidneys and lower blood pressure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 532 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2017

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * CKD 3b or 4 (45 - 15 ml/min/1.73 m2) * Δ eGFR (as estimated by the CKD-EPI equation) \> 2 ml/min/1.73 m2/year (in preceding ≥ 1 year with at least 3 measurements) * Hypertension (defined as office blood pressure \> 140/90 mmHg or use of anti-hypertensive medication) Exclusion Criteria: * Hyperkalemia (serum potassium \> 5.5 mmol/l) at study visit V0 * Medical reasons to continue dual RAAS-blockade, mineralocorticoid receptor blockers, potassium-sparing diuretics, or oral potassium binders. * Patients with previous history of ventricular cardiac arrhythmia * Patients with a life expectancy \< 6 months * Expected initiation of renal replacement therapy \< 2 years * Incapacitated subjects * Women who are pregnant, breastfeeding or consider pregnancy in the coming 2 years.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hyperkalemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome Hyperkalemia hypertensive disorder potassium deficiency potassium deficiency disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hyperkalemia Hypertension Potassium depletion Renal insufficiency, chronic

Contacts and locations

Locations

  • Academic Medical Center Amsterdam

    Amsterdam, Netherlands

  • Erasmus MC

    Rotterdam, Netherlands

  • Leiden University Medical Center

    Leiden, Netherlands

  • University Medical Center Groningen

    Groningen, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.